
- ImmunoPrecise Antibodies (IPA) shows strong technical momentum, hitting new 52-week highs on Aug. 21.
- The stock maintains a 100% “Buy” opinion from Barchart.
- Shares are up an impressive 565% in 2025.
- Despite bullish analyst sentiment, IPA is volatile and speculative.